MHC multimer technology: current status and future prospects
- 20 June 2005
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 17 (4) , 428-433
- https://doi.org/10.1016/j.coi.2005.06.008
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Soluble Major Histocompatibility Complex-Peptide Octamers with Impaired CD8 Binding Selectively Induce Fas-dependent ApoptosisJournal of Biological Chemistry, 2003
- The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II OligomersImmunity, 2000
- Isolation of HIV-1-specific cytotoxic T lymphocytes using human leukocyte antigen-coated beadsAIDS, 1999
- Initiation of Signal Transduction through the T Cell Receptor Requires the Multivalent Engagement of Peptide/MHC LigandsImmunity, 1998
- Direct visualization of antigen-specific T cells: HTLV-1 Tax11–19- specific CD8+T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsProceedings of the National Academy of Sciences, 1998
- A New Look at T CellsThe Journal of Experimental Medicine, 1998
- LIGAND RECOGNITION BY αβ T CELL RECEPTORSAnnual Review of Immunology, 1998
- Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapyNature Biotechnology, 1998
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.Proceedings of the National Academy of Sciences, 1993